Posted by Michael Wonder on 08 Aug 2021
US tropical disease priority review vouchers: lessons in promoting drug development and access
6 August 2021 - The COVID-19 global pandemic has devastated lives and economies. It has served as a reminder of how critical it is to invest in preventing and treating infectious diseases.
Until the COVID-19 pandemic, the largest US government–sponsored reward for infectious disease drug and vaccine development was the Tropical Disease Priority Review Voucher program.
Under this program, the FDA awards a priority review voucher to the sponsor of a new drug or vaccine for tropical infectious diseases.
